225 related articles for article (PubMed ID: 32037952)
1. APC-β-catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axis.
Blomain ES; Rappaport JA; Pattison AM; Bashir B; Caparosa E; Stem J; Snook AE; Waldman SA
Cancer Biol Ther; 2020 May; 21(5):441-451. PubMed ID: 32037952
[TBL] [Abstract][Full Text] [Related]
2. A β-Catenin-TCF-Sensitive Locus Control Region Mediates GUCY2C Ligand Loss in Colorectal Cancer.
Rappaport JA; Entezari AA; Caspi A; Caksa S; Jhaveri AV; Stanek TJ; Ertel A; Kupper J; Fortina PM; McMahon SB; Jaynes JB; Snook AE; Waldman SA
Cell Mol Gastroenterol Hepatol; 2022; 13(4):1276-1296. PubMed ID: 34954189
[TBL] [Abstract][Full Text] [Related]
3. Silencing the intestinal GUCY2C tumor suppressor axis requires
Pattison AM; Barton JR; Entezari AA; Zalewski A; Rappaport JA; Snook AE; Waldman SA
Cancer Biol Ther; 2020 Sep; 21(9):799-805. PubMed ID: 32594830
[TBL] [Abstract][Full Text] [Related]
4. Obesity-Induced Colorectal Cancer Is Driven by Caloric Silencing of the Guanylin-GUCY2C Paracrine Signaling Axis.
Lin JE; Colon-Gonzalez F; Blomain E; Kim GW; Aing A; Stoecker B; Rock J; Snook AE; Zhan T; Hyslop TM; Tomczak M; Blumberg RS; Waldman SA
Cancer Res; 2016 Jan; 76(2):339-46. PubMed ID: 26773096
[TBL] [Abstract][Full Text] [Related]
5. The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer.
Wilson C; Lin JE; Li P; Snook AE; Gong J; Sato T; Liu C; Girondo MA; Rui H; Hyslop T; Waldman SA
Cancer Epidemiol Biomarkers Prev; 2014 Nov; 23(11):2328-37. PubMed ID: 25304930
[TBL] [Abstract][Full Text] [Related]
6. Intestinal GUCY2C prevents TGF-β secretion coordinating desmoplasia and hyperproliferation in colorectal cancer.
Gibbons AV; Lin JE; Kim GW; Marszalowicz GP; Li P; Stoecker BA; Blomain ES; Rattan S; Snook AE; Schulz S; Waldman SA
Cancer Res; 2013 Nov; 73(22):6654-66. PubMed ID: 24085786
[TBL] [Abstract][Full Text] [Related]
7. Guanylyl Cyclase C Hormone Axis at the Intersection of Obesity and Colorectal Cancer.
Blomain ES; Merlino DJ; Pattison AM; Snook AE; Waldman SA
Mol Pharmacol; 2016 Sep; 90(3):199-204. PubMed ID: 27251363
[TBL] [Abstract][Full Text] [Related]
8. Silencing the GUCA2A-GUCY2C tumor suppressor axis in CIN, serrated, and MSI colorectal neoplasia.
Bashir B; Merlino DJ; Rappaport JA; Gnass E; Palazzo JP; Feng Y; Fearon ER; Snook AE; Waldman SA
Hum Pathol; 2019 May; 87():103-114. PubMed ID: 30716341
[TBL] [Abstract][Full Text] [Related]
9. Targeting the paracrine hormone-dependent guanylate cyclase/cGMP/phosphodiesterases signaling pathway for colorectal cancer prevention.
Yarla NS; Gali H; Pathuri G; Smriti S; Farooqui M; Panneerselvam J; Kumar G; Madka V; Rao CV
Semin Cancer Biol; 2019 Jun; 56():168-174. PubMed ID: 30189250
[TBL] [Abstract][Full Text] [Related]
10. Guanylyl cyclase C signaling axis and colon cancer prevention.
Pattison AM; Merlino DJ; Blomain ES; Waldman SA
World J Gastroenterol; 2016 Sep; 22(36):8070-7. PubMed ID: 27688649
[TBL] [Abstract][Full Text] [Related]
11. Beta-catenin/Tcf-4 inhibition after progastrin targeting reduces growth and drives differentiation of intestinal tumors.
Pannequin J; Delaunay N; Buchert M; Surrel F; Bourgaux JF; Ryan J; Boireau S; Coelho J; Pélegrin A; Singh P; Shulkes A; Yim M; Baldwin GS; Pignodel C; Lambeau G; Jay P; Joubert D; Hollande F
Gastroenterology; 2007 Nov; 133(5):1554-68. PubMed ID: 17920061
[TBL] [Abstract][Full Text] [Related]
12. GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome.
Li P; Wuthrick E; Rappaport JA; Kraft C; Lin JE; Marszalowicz G; Snook AE; Zhan T; Hyslop TM; Waldman SA
Cancer Res; 2017 Sep; 77(18):5095-5106. PubMed ID: 28916678
[TBL] [Abstract][Full Text] [Related]
13. The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling.
Lin JE; Li P; Snook AE; Schulz S; Dasgupta A; Hyslop TM; Gibbons AV; Marszlowicz G; Pitari GM; Waldman SA
Gastroenterology; 2010 Jan; 138(1):241-54. PubMed ID: 19737566
[TBL] [Abstract][Full Text] [Related]
14. Can colorectal cancer be prevented or treated by oral hormone replacement therapy?
Li P; Lin JE; Schulz S; Pitari GM; Waldman SA
Curr Mol Pharmacol; 2009 Nov; 2(3):285-92. PubMed ID: 20021465
[TBL] [Abstract][Full Text] [Related]
15. TCF-3, 4 protein expression correlates with beta-catenin expression in MSS and MSI-H colorectal cancer from HNPCC patients but not in sporadic colorectal cancers.
Balaz P; Plaschke J; Krüger S; Görgens H; Schackert HK
Int J Colorectal Dis; 2010 Aug; 25(8):931-9. PubMed ID: 20532534
[TBL] [Abstract][Full Text] [Related]
16. RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis.
Ito K; Lim AC; Salto-Tellez M; Motoda L; Osato M; Chuang LS; Lee CW; Voon DC; Koo JK; Wang H; Fukamachi H; Ito Y
Cancer Cell; 2008 Sep; 14(3):226-37. PubMed ID: 18772112
[TBL] [Abstract][Full Text] [Related]
17. Activator protein 2alpha suppresses intestinal tumorigenesis in the Apc(min) mouse.
Li Q; Löhr CV; Dashwood RH
Cancer Lett; 2009 Sep; 283(1):36-42. PubMed ID: 19376641
[TBL] [Abstract][Full Text] [Related]
18. An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer.
Rappaport JA; Waldman SA
Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1125-1137. PubMed ID: 32945718
[No Abstract] [Full Text] [Related]
19. Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention.
Weinberg DS; Lin JE; Foster NR; Della'Zanna G; Umar A; Seisler D; Kraft WK; Kastenberg DM; Katz LC; Limburg PJ; Waldman SA
Cancer Prev Res (Phila); 2017 Jun; 10(6):345-354. PubMed ID: 28396341
[TBL] [Abstract][Full Text] [Related]
20. Chromosomal instability by beta-catenin/TCF transcription in APC or beta-catenin mutant cells.
Aoki K; Aoki M; Sugai M; Harada N; Miyoshi H; Tsukamoto T; Mizoshita T; Tatematsu M; Seno H; Chiba T; Oshima M; Hsieh CL; Taketo MM
Oncogene; 2007 May; 26(24):3511-20. PubMed ID: 17160019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
